Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cognition Therapeutics, Inc. (CGTX)
USD0.94
-0.07 (-6.65%)
US NASDAQ Healthcare Biotechnology
Address
2500 Westchester Avenue 10577
Purchase, NY, US
Purchase, NY, US
CEO
Lisa Ricciardi
Website
cogrx.com
IPO
2021-10-08
CIK 1455365 ISIN US19243B1026
Description
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.94
-0.07 (-6.65%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
1.75
Float Shares
59.14M
Free Float %
80.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -4.84% | +30.44% | +10.28% | -31.40% | -12.59% | +260.97% | -26.25% | -90.76% | -90.76% | -90.76% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (7 ratings, all time)
Buy
Price Targets & DCF
Current price
0.94
DCF (Unlevered)
0.60
-35.9%
DCF (Levered)
0.50
-47.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-0.70
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+62.4% ★ Q1'26: +63.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +4,677.5% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+83.2% Q1'26: +44.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.03× Q1'26: -0.01× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 3 EPS Ana. |
Dec 2027 2 Rev. Ana. 3 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
est: 16.00M (-100.0%)
|
18.70M
18.70M – 18.70M
+16.9% YoY
|
41.93M
41.93M – 41.93M
+124.2% YoY
|
4.30M
4.30M – 4.30M
-89.7% YoY
|
45.10M
45.10M – 45.10M
+948.8% YoY
|
112.50M
112.50M – 112.50M
+149.4% YoY
|
| EBITDA |
-33.68M
|
-23.25M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-33.95M
|
-23.47M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-33.97M
est: -32.99M (-3.0%)
|
-23.49M
est: -28.38M (+17.2%)
|
-19.10M
-29.29M – -8.91M
+32.7% YoY
|
-21.20M
-30.72M – -11.67M
-11.0% YoY
|
-21.10M
-21.10M – -21.10M
+0.5% YoY
|
-18.19M
-18.19M – -18.19M
+13.8% YoY
|
-13.83M
-13.83M – -13.83M
+24.0% YoY
|
| SGA |
12.29M
|
10.61M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-0.85
est: -0.82 (-3.4%)
|
-0.32
est: -0.39 (+17.9%)
|
-0.28
-0.40 – -0.12
+28.2% YoY
|
-0.25
-0.42 – -0.16
+9.5% YoY
|
-0.29
-0.29 – -0.29
-14.5% YoY
|
-0.25
-0.25 – -0.25
+13.8% YoY
|
-0.19
-0.19 – -0.19
+24.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
9
Total invested
2.30M
Insider transactions (90d)
1
Beneficial owners (>5%)
23
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AARON GLENN LOUIS FLETCHER | 3.93M | 17.80% | — | 3.93M | — | 11.00 | IN | — | 2022-02-01 | ↗ |
| 2 | BIOS ADVISORS GP, LLC | 3.91M | 17.80% | — | 3.91M | — | 11.00 | OO | — | 2022-02-01 | ↗ |
| 3 | BIOS CAPITAL MANAGEMENT, LP | 3.91M | 17.80% | — | 3.91M | — | 11.00 | PN | — | 2022-02-01 | ↗ |
| 4 | CAVU ADVISORS, LLC | 3.91M | 17.80% | — | 3.91M | — | 11.00 | OO | — | 2022-02-01 | ↗ |
| 5 | CAVU MANAGEMENT, LP | 3.91M | 17.80% | — | 3.91M | — | 11.00 | PN | — | 2022-02-01 | ↗ |
| 6 | LESLIE WAYNE KREIS, JR. | 3.91M | 17.80% | — | 3.91M | — | 11.00 | IN | — | 2022-02-01 | ↗ |
| 7 | Pathstone Family Office, LLC | 2.21M | 7.53% | — | — | — | — | IA | Delaware | 2024-01-19 | ↗ |
| 8 | 27-4413262 | 2.04M | 7.00% | 2.04M | — | 2.04M | — | OO | Maryland | 2022-11-18 | ↗ |
| 9 | Identification Nos. of above persons (. | 2.04M | 7.00% | 2.04M | — | 2.04M | — | IN | Maryland | 2022-11-18 | ↗ |
| 10 | BIOS MEMORY SPV I, LP | 1.42M | 6.50% | — | 1.42M | — | 11.00 | PN | — | 2022-02-01 | ↗ |
| 11 | BIOS EQUITY PARTNERS III, LP | 1.07M | 4.90% | — | 1.07M | — | 11.00 | PN | — | 2022-02-01 | ↗ |
| 12 | BIOS EQUITY PARTNERS, LP | 1.05M | 4.80% | — | 1.05M | — | 11.00 | PN | — | 2022-02-01 | ↗ |
| 13 | BIOS FUND III QP, LP | 814.6K | 3.70% | — | 814.6K | — | 11.00 | PN | — | 2022-02-01 | ↗ |
| 14 | BIOS FUND I, LP | 418.9K | 1.90% | — | 418.9K | — | 11.00 | PN | — | 2022-02-01 | ↗ |
| 15 | BIOS MEMORY SPV II, LP | 385.2K | 1.70% | — | 385.2K | — | 11.00 | PN | — | 2022-02-01 | ↗ |
| 16 | BIOS EQUITY PARTNERS II, LP | 368.3K | 1.70% | — | 368.3K | — | 11.00 | PN | — | 2022-02-01 | ↗ |
| 17 | BIOS FUND II QP, LP | 255.8K | 1.20% | — | 255.8K | — | 11.00 | PN | — | 2022-02-01 | ↗ |
| 18 | BIOS FUND I QP, LP | 245.0K | 1.10% | — | 245.0K | — | 11.00 | PN | — | 2022-02-01 | ↗ |
| 19 | BIOS FUND III NT, LP | 131.8K | 0.60% | — | 131.8K | — | 11.00 | PN | — | 2022-02-01 | ↗ |
| 20 | BIOS FUND III, LP | 124.9K | 0.60% | — | 124.9K | — | 11.00 | PN | — | 2022-02-01 | ↗ |
| 21 | BIOS FUND II, LP | 78.3K | 0.40% | — | 78.3K | — | 11.00 | PN | — | 2022-02-01 | ↗ |
| 22 | BIOS FUND II NT, LP | 34.2K | 0.20% | — | 34.2K | — | 11.00 | PN | — | 2022-02-01 | ↗ |
| 23 | BP DIRECTORS, LP | 572.00 | 0.10% | — | 572.00 | — | 11.00 | PN | — | 2022-02-01 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
9
-69 vs prev Q
New positions
1
Closed positions
70
Increased
5
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BIOS CAPITAL MANAGEMENT, LP | 6.00M +— (+0.0%) | 8.10M +1.0 (+0.0%) | 7.70% -1.723 pp | 9.80% +0.694 pp | USD0.70 +92.9% | 5 qtrs — |
| 2 | VANGUARD GROUP INC | 3.32M +635.9K (+23.7%) | 4.48M +858.5K (+23.7%) | 4.26% +0.046 pp | 0.00% +0.000 pp | USD1.56 -13.5% | 17 qtrs — |
| 3 | DAVENPORT & CO LLC | 2.87M +182.5K (+6.8%) | 3.88M +246.4K (+6.8%) | 3.68% -0.538 pp | 0.02% +0.001 pp | USD1.35 +0.0% | 2 qtrs — |
| 4 | BLACKROCK, INC. | 1.01M +45.6K (+4.7%) | 1.37M +61.6K (+4.7%) | 1.30% -0.220 pp | 0.00% +0.000 pp | USD1.28 +5.5% | 6 qtrs — |
| 5 | CHESCAPMANAGER LLC | 997.0K +— (+0.0%) | 1.35M +— (+0.0%) | 1.28% -0.286 pp | 0.11% -0.017 pp | USD0.82 +64.6% | 3 qtrs — |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 969.5K +256.0K (+35.9%) | 1.31M +345.6K (+35.9%) | 1.24% +0.124 pp | 0.00% +0.001 pp | USD1.34 +0.7% | 9 qtrs — |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 874.0K +161.2K (+22.6%) | 1.18M +217.6K (+22.6%) | 1.12% +0.002 pp | 0.00% +0.000 pp | USD1.39 -2.9% | 16 qtrs — |
| 8 | JANE STREET GROUP, LLC | 614.3K -311.9K (-33.7%) | 829.3K -421.1K (-33.7%) | 0.79% -0.666 pp | 0.00% 0.000 pp | USD1.34 +0.7% | 6 qtrs — |
| 9 | HILTON CAPITAL MANAGEMENT, LLC | 549.0K -32.2K (-5.5%) | 741.1K -43.5K (-5.5%) | 0.70% -0.208 pp | 0.06% -0.008 pp | USD1.35 +0.0% | 2 qtrs — |
| 10 | DAUNTLESS INVESTMENT GROUP, LLC | 466.0K +466.0K (+100.0%) | 629.1K +629.1K (+100.0%) | 0.60% +0.598 pp | 0.50% +0.500 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 11 | STATE STREET CORP | 314.5K -10.5K (-3.2%) | 424.6K -14.2K (-3.2%) | 0.40% -0.107 pp | 0.00% +0.000 pp | USD1.31 +3.1% | 14 qtrs — |
| 12 | VOSS CAPITAL, LLC | 279.3K -20.7K (-6.9%) | 377.1K -27.9K (-6.9%) | 0.36% -0.113 pp | 0.02% -0.002 pp | USD0.70 +92.9% | 5 qtrs — |
| 13 | SIGMA PLANNING CORP | 216.2K +89.1K (+70.1%) | 294.5K +123.0K (+71.7%) | 0.28% +0.078 pp | 0.01% +0.003 pp | USD1.16 +16.4% | 9 qtrs — |
| 14 | AMERICAN FINANCIAL GROUP INC | 205.0K +— (+0.0%) | 276.8K +— (+0.0%) | 0.26% -0.059 pp | 0.10% -0.006 pp | USD6.32 -78.6% | 17 qtrs — |
| 15 | CM MANAGEMENT, LLC | 200.0K +200.0K (+100.0%) | 270.0K +270.0K (+100.0%) | 0.26% +0.257 pp | 0.23% +0.228 pp | USD1.35 +0.0% | 8 qtrs — |
| 16 | NORTHERN TRUST CORP | 194.3K +49.1K (+33.8%) | 262.3K +66.2K (+33.8%) | 0.25% +0.021 pp | 0.00% +0.000 pp | USD1.50 -10.0% | 14 qtrs — |
| 17 | TOCQUEVILLE ASSET MANAGEMENT L.P. | 192.5K +30.0K (+18.5%) | 259.9K +40.5K (+18.5%) | 0.25% -0.008 pp | 0.00% +0.001 pp | USD1.39 -2.9% | 8 qtrs — |
| 18 | CITADEL ADVISORS LLC | 161.2K +161.2K (+100.0%) | 217.6K +217.6K (+100.0%) | 0.21% +0.207 pp | 0.00% +0.000 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 19 | OMERS ADMINISTRATION CORP | 159.6K +159.6K (+100.0%) | 215.5K +215.5K (+100.0%) | 0.20% +0.205 pp | 0.00% +0.002 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 20 | GRAHAM CAPITAL MANAGEMENT, L.P. | 151.9K -74.7K (-33.0%) | 205.0K -100.8K (-33.0%) | 0.19% -0.161 pp | 0.00% +0.000 pp | USD1.35 +0.0% | 2 qtrs — |
| 21 | TEXAS CAPITAL BANK WEALTH MANAGEMENT SERVICES INC | 123.3K +123.3K (+100.0%) | 166.5K +166.5K (+100.0%) | 0.16% +0.158 pp | 0.01% +0.010 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 22 | MORGAN STANLEY | 93.3K +60.6K (+185.5%) | 126.0K +81.9K (+185.5%) | 0.12% +0.068 pp | 0.00% +0.000 pp | USD1.11 +21.6% | 15 qtrs — |
| 23 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 84.9K +— (+0.0%) | 114.7K +— (+0.0%) | 0.11% -0.024 pp | 0.00% +0.000 pp | USD1.35 +0.0% | 2 qtrs — |
| 24 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 80.0K +80.0K (+100.0%) | 108.0K +108.0K (+100.0%) | 0.10% +0.103 pp | 0.00% +0.000 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 25 | UBS GROUP AG | 74.3K +8.3K (+12.6%) | 100.3K +11.2K (+12.6%) | 0.10% -0.008 pp | 0.00% +0.000 pp | USD1.19 +13.4% | 6 qtrs — |
| 26 | MCADAM, LLC | 74.1K +2.0K (+2.8%) | 100.0K +2.7K (+2.8%) | 0.10% -0.018 pp | 0.00% 0.000 pp | USD1.35 +0.0% | 2 qtrs — |
| 27 | CI PRIVATE WEALTH, LLC | 72.1K +— (+0.0%) | 97.4K +— (+0.0%) | 0.09% -0.021 pp | 0.00% +0.000 pp | USD1.35 +0.0% | 2 qtrs — |
| 28 | MILLENNIUM MANAGEMENT LLC | 64.7K -495.9K (-88.5%) | 87.3K -669.5K (-88.5%) | 0.08% -0.797 pp | 0.00% 0.000 pp | USD1.35 +0.0% | 2 qtrs — |
| 29 | FCA CORP /TX | 52.5K +— (+0.0%) | 70.9K +— (+0.0%) | 0.07% -0.015 pp | 0.02% +0.000 pp | USD1.95 -30.8% | 12 qtrs — |
| 30 | CIRCLE WEALTH MANAGEMENT, LLC | 48.8K +— (+0.0%) | 65.9K +— (+0.0%) | 0.06% -0.014 pp | 0.00% 0.000 pp | USD1.90 -28.9% | 8 qtrs — |
| 31 | RAYMOND JAMES FINANCIAL INC | 48.5K +18.9K (+63.6%) | 65.5K +25.5K (+63.6%) | 0.06% +0.016 pp | 0.00% +0.000 pp | USD1.03 +31.1% | 5 qtrs — |
| 32 | EMPIRICAL FINANCIAL SERVICES, LLC D.B.A. EMPIRICAL WEALTH MANAGEMENT | 48.0K +— (+0.0%) | 64.8K +— (+0.0%) | 0.06% -0.014 pp | 0.00% 0.000 pp | USD0.31 +335.5% | 3 qtrs — |
| 33 | TWO SIGMA INVESTMENTS, LP | 47.7K -49.3K (-50.8%) | 64.4K -66.5K (-50.8%) | 0.06% -0.091 pp | 0.00% 0.000 pp | USD0.55 +145.5% | 6 qtrs — |
| 34 | CASTLE WEALTH MANAGEMENT LLC | 44.0K +— (+0.0%) | 59.4K +— (+0.0%) | 0.06% -0.013 pp | 0.02% 0.000 pp | USD2.08 -35.1% | 15 qtrs — |
| 35 | CETERA INVESTMENT ADVISERS | 41.2K -19.0K (-31.6%) | 55.6K -25.7K (-31.6%) | 0.05% -0.042 pp | 0.00% +0.000 pp | USD1.17 +15.4% | 3 qtrs — |
| 36 | VIRTU FINANCIAL LLC | 40.0K +40.0K (+100.0%) | 54.0K +54.0K (+100.0%) | 0.05% +0.051 pp | 0.00% +0.002 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 37 | XTX TOPCO LTD | 37.2K +37.2K (+100.0%) | 50.3K +50.3K (+100.0%) | 0.05% +0.048 pp | 0.00% +0.001 pp | USD1.35 +0.0% | 3 qtrs — |
| 38 | BANGOR SAVINGS BANK | 34.0K +— (+0.0%) | 45.9K +— (+0.0%) | 0.04% -0.010 pp | 0.00% 0.000 pp | USD2.29 -41.0% | 16 qtrs — |
| 39 | CREATIVE PLANNING | 30.0K +— (+0.0%) | 40.5K +— (+0.0%) | 0.04% -0.009 pp | 0.00% +0.000 pp | USD0.62 +117.7% | 4 qtrs — |
| 40 | JONES FINANCIAL COMPANIES LLLP | 29.7K +11.2K (+60.7%) | 40.1K +15.5K (+63.1%) | 0.04% +0.009 pp | 0.00% +0.000 pp | USD1.35 +0.0% | 2 qtrs — |
| 41 | LIGHTHOUSE INVESTMENT PARTNERS, LLC | 29.6K +29.6K (+100.0%) | 39.9K +39.9K (+100.0%) | 0.04% +0.038 pp | 0.00% +0.001 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 42 | QUADRATURE CAPITAL LTD | 29.5K -233.6K (-88.8%) | 39.8K -318.0K (-88.9%) | 0.04% -0.375 pp | 0.00% -0.004 pp | USD1.35 +0.0% | 2 qtrs — |
| 43 | BRYN MAWR CAPITAL MANAGEMENT, LLC | 29.1K -10.4K (-26.4%) | 39.2K -14.1K (-26.4%) | 0.04% -0.025 pp | 0.00% -0.001 pp | USD0.97 +39.2% | 5 qtrs — |
| 44 | TWO SIGMA SECURITIES, LLC | 28.6K +28.6K (+100.0%) | 38.7K +38.7K (+100.0%) | 0.04% +0.037 pp | 0.01% +0.005 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 45 | MARSHALL WACE, LLP | 27.6K +27.6K (+100.0%) | 37.2K +37.2K (+100.0%) | 0.04% +0.035 pp | 0.00% +0.000 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 46 | CWA ASSET MANAGEMENT GROUP, LLC | 25.3K +— (+0.0%) | 34.1K +— (+0.0%) | 0.03% -0.007 pp | 0.00% +0.000 pp | USD1.35 +0.0% | 2 qtrs — |
| 47 | PRIVATE MANAGEMENT GROUP INC | 24.0K +— (+0.0%) | 32.4K +— (+0.0%) | 0.03% -0.007 pp | 0.00% +0.000 pp | USD1.35 +0.0% | 2 qtrs — |
| 48 | HIGHTOWER ADVISORS, LLC | 24.0K -500.0 (-2.0%) | 32.4K -675.0 (-2.0%) | 0.03% -0.008 pp | 0.00% +0.000 pp | USD1.51 -10.6% | 12 qtrs — |
| 49 | ESSEX FINANCIAL SERVICES, INC. | 20.0K +20.0K (+100.0%) | 27.0K +27.0K (+100.0%) | 0.03% +0.026 pp | 0.00% +0.002 pp | USD1.35 +0.0% | 4 qtrs — |
| 50 | GAMCO INVESTORS, INC. ET AL | 20.0K +— (+0.0%) | 27.0K +— (+0.0%) | 0.03% -0.006 pp | 0.00% +0.000 pp | USD1.35 +0.0% | 2 qtrs — |
| 51 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 19.2K +— (+0.0%) | 26.0K +— (+0.0%) | 0.02% -0.006 pp | 0.00% +0.000 pp | USD1.35 +0.0% | 2 qtrs — |
| 52 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 17.5K +— (+0.0%) | 23.6K +— (+0.0%) | 0.02% -0.005 pp | 0.00% +0.000 pp | USD0.96 +40.6% | 13 qtrs — |
| 53 | QUBE RESEARCH & TECHNOLOGIES LTD | 17.1K +17.1K (+100.0%) | 23.1K +23.1K (+100.0%) | 0.02% +0.022 pp | 0.00% +0.000 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 54 | MERCER GLOBAL ADVISORS INC /ADV | 16.0K +— (+0.0%) | 21.5K +— (+0.0%) | 0.02% -0.005 pp | 0.00% +0.000 pp | USD1.80 -25.0% | 11 qtrs — |
| 55 | COLONY GROUP, LLC | 15.0K +— (+0.0%) | 20.3K +— (+0.0%) | 0.02% -0.004 pp | 0.00% +0.000 pp | USD1.35 +0.0% | 2 qtrs — |
| 56 | BESSEMER GROUP INC | 13.8K +— (+0.0%) | 19.0K +— (+0.0%) | 0.02% -0.004 pp | 0.00% +0.000 pp | USD0.47 +187.2% | 6 qtrs — |
| 57 | CITIZENS FINANCIAL GROUP INC/RI | 13.7K +— (+0.0%) | 18.5K +— (+0.0%) | 0.02% -0.004 pp | 0.00% +0.000 pp | USD1.35 +0.0% | 2 qtrs — |
| 58 | GSA CAPITAL PARTNERS LLP | 11.8K -184.5K (-94.0%) | 16.0K -249.0K (-94.0%) | 0.02% -0.293 pp | 0.00% -0.021 pp | USD1.35 +0.0% | 4 qtrs — |
| 59 | BRADLEY FOSTER & SARGENT INC/CT | 11.7K +— (+0.0%) | 15.8K +— (+0.0%) | 0.02% -0.003 pp | 0.00% +0.000 pp | USD0.42 +221.4% | 4 qtrs — |
| 60 | CHICAGO PARTNERS INVESTMENT GROUP LLC | 10.9K +— (+0.0%) | 15.6K -1.7K (-10.1%) | 0.01% -0.003 pp | 0.00% 0.000 pp | USD0.43 +214.0% | 4 qtrs — |
| 61 | LPL FINANCIAL LLC | 11.5K -3.8K (-24.7%) | 15.5K -5.1K (-24.7%) | 0.01% -0.009 pp | 0.00% +0.000 pp | USD1.35 +0.0% | 2 qtrs — |
| 62 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 10.0K -1.0K (-9.1%) | 14.1K -5.2K (-26.8%) | 0.01% -0.004 pp | 0.00% +0.000 pp | USD0.76 +77.6% | 5 qtrs — |
| 63 | SQUAREPOINT OPS LLC | 10.4K +10.4K (+100.0%) | 14.0K +14.0K (+100.0%) | 0.01% +0.013 pp | 0.00% +0.000 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 64 | MML INVESTORS SERVICES, LLC | 10.0K +— (+0.0%) | 13.5K +— (+0.0%) | 0.01% -0.003 pp | 0.00% +0.000 pp | USD1.35 +0.0% | 2 qtrs — |
| 65 | RETIREMENT PLANNING GROUP | 10.0K +— (+0.0%) | 13.5K +— (+0.0%) | 0.01% -0.003 pp | 0.00% +0.000 pp | USD0.42 +221.4% | 4 qtrs — |
| 66 | ROBERTSON STEPHENS WEALTH MANAGEMENT, LLC | 10.0K +— (+0.0%) | 13.5K +— (+0.0%) | 0.01% -0.003 pp | 0.00% 0.000 pp | USD1.35 +0.0% | 2 qtrs — |
| 67 | STONEX GROUP INC. | 10.0K +10.0K (+100.0%) | 13.5K +13.5K (+100.0%) | 0.01% +0.013 pp | 0.00% +0.001 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 68 | BARRY INVESTMENT ADVISORS, LLC | 10.0K +— (+0.0%) | 13.5K +— (+0.0%) | 0.01% -0.003 pp | 0.00% 0.000 pp | USD1.35 +0.0% | 2 qtrs — |
| 69 | BANK OF AMERICA CORP /DE/ | 5.7K +140.0 (+2.5%) | 7.7K +190.0 (+2.5%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD1.32 +2.3% | 10 qtrs — |
| 70 | FIFTH THIRD BANCORP | 5.0K +5.0K (+100.0%) | 6.8K +6.8K (+100.0%) | 0.01% +0.006 pp | 0.00% +0.000 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 71 | ADVISOR GROUP HOLDINGS, INC. | 4.6K -8.0K (-63.5%) | 6.2K -11.8K (-65.5%) | 0.01% -0.014 pp | 0.00% +0.000 pp | USD0.45 +200.0% | 8 qtrs — |
| 72 | WELLS FARGO & COMPANY/MN | 3.0K -1.0K (-25.0%) | 4.1K -1.4K (-25.0%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD1.44 -6.2% | 15 qtrs — |
| 73 | VERSANT CAPITAL MANAGEMENT, INC | 2.0K +2.0K (+100.0%) | 2.7K +2.7K (+100.0%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 74 | GLOBAL RETIREMENT PARTNERS, LLC | 2.0K +— (+0.0%) | 2.7K +— (+0.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD1.35 +0.0% | 2 qtrs — |
| 75 | MAI CAPITAL MANAGEMENT | 250.00 +— (+0.0%) | 338.00 +— (+0.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD0.83 +62.7% | 5 qtrs — |
| 76 | CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | 99.00 +54.0 (+120.0%) | 134.00 +73.0 (+119.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.33 +1.5% | 2 qtrs — |
| 77 | SBI SECURITIES CO., LTD. | 5.00 +4.0 (+400.0%) | 7.00 +6.0 (+600.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.00 +35.0% | 4 qtrs — |
| 78 | FMR LLC | 1.00 +— (+0.0%) | 1.00 +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.00 +35.0% | 2 qtrs — |
| 79 | ALYESKA INVESTMENT GROUP, L.P. | — -102.1K (-100.0%) | — -137.8K (-100.0%) | 0.00% -0.160 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 80 | EVERHART FINANCIAL GROUP, INC. | — -31.7K (-100.0%) | — -42.8K (-100.0%) | 0.00% -0.050 pp | 0.00% -0.004 pp | USD— | 2 qtrs SOLD |
| 81 | TANG CAPITAL MANAGEMENT LLC | — -1.2M (-100.0%) | — -1.6M (-100.0%) | 0.00% -1.884 pp | 0.00% -0.062 pp | USD— | 2 qtrs SOLD |
| 82 | REGIONS FINANCIAL CORP | — -15.7K (-100.0%) | — -21.2K (-100.0%) | 0.00% -0.025 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 83 | TOWER RESEARCH CAPITAL LLC (TRC) | — -2.0K (-100.0%) | — -2.7K (-100.0%) | 0.00% -0.003 pp | 0.00% 0.000 pp | USD— | 15 qtrs SOLD |
| 84 | IFP ADVISORS, INC | — -1.0K (-100.0%) | — -1.4K (-100.0%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 85 | NOVA WEALTH MANAGEMENT, INC. | — -500.0 (-100.0%) | — -675.0 (-100.0%) | 0.00% -0.001 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 86 | ADVISORY SERVICES NETWORK, LLC | — -2.5K (-100.0%) | — -3.4K (-100.0%) | 0.00% -0.004 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 12 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.02% | 300.0K | 0.60% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 1.01M | 0.05% |
| 3 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 5.5K | 0.03% |
| 4 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 15.2K | 0.17% |
| 5 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 1.1K | 0.17% |
| 6 | Vanguard Total Stock Market ETF VTI | 0.00% | 2.59M | 0.03% |
| 7 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 5.7K | 0.22% |
| 8 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 3.1K | 0.22% |
| 9 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 1.2K | 0.22% |
| 10 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 137.51 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.60
Neutral
Ratio by volume
3.00
Bullish
Buys
3
Sells
5
Shares acquired
1.40M
Shares disposed
143.1K
Cash buys
—
Cash sales
—
Net activity
+1,256,932
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | Doyle John Brendan | Officer | F-InKind | D | Common Stock | 8,567 | 1.28 | 11.0K | 618,942 | D | ↗ |
| 2026-04-16 | Ricciardi Lisa | Director / Officer | P-Purchase | A | Common Stock | 9,175 | 1.10 | 10.1K | 1,715,851 | D | ↗ |
| 2026-04-16 | Doyle John Brendan | Officer | P-Purchase | A | Common Stock | 10,000 | 1.13 | 11.3K | 627,509 | D | ↗ |
| 2026-04-16 | Caggiano Anthony | Officer | P-Purchase | A | Common Stock | 10,000 | 1.11 | 11.1K | 874,906 | D | ↗ |
| 2026-02-15 | Ricciardi Lisa | Director / Officer | F-InKind | D | Common Stock | 5,850 | 1.12 | 6.6K | 1,706,676 | D | ↗ |
| 2026-02-15 | Doyle John Brendan | Officer | F-InKind | D | Common Stock | 1,560 | 1.12 | 1.7K | 617,509 | D | ↗ |
| 2026-02-15 | Caggiano Anthony | Officer | F-InKind | D | Common Stock | 4,680 | 1.12 | 5.2K | 864,906 | D | ↗ |
| 2026-02-04 | Ricciardi Lisa | Director / Officer | F-InKind | D | Common Stock | 51,704 | 1.03 | 53.3K | 1,712,526 | D | ↗ |
| 2026-02-04 | Doyle John Brendan | Officer | F-InKind | D | Common Stock | 26,921 | 1.03 | 27.7K | 619,069 | D | ↗ |
| 2026-02-04 | Caggiano Anthony | Officer | F-InKind | D | Common Stock | 26,919 | 1.03 | 27.7K | 869,586 | D | ↗ |
| 2026-02-03 | Ricciardi Lisa | Director / Officer | F-InKind | D | Common Stock | 26,036 | 1.12 | 29.2K | 1,764,230 | D | ↗ |
| 2026-02-03 | Doyle John Brendan | Officer | A-Award | A | Common Stock | 200,000 | 0.00 | — | 645,990 | D | ↗ |
| 2026-02-03 | Caggiano Anthony | Officer | F-InKind | D | Common Stock | 11,488 | 1.12 | 12.9K | 896,505 | D | ↗ |
| 2025-12-18 | Ricciardi Lisa | Director / Officer | A-Award | A | Common Stock | 75,000 | 0.00 | — | 1,013,666 | D | ↗ |
| 2025-12-18 | Doyle John Brendan | Officer | F-InKind | D | Common Stock | 9,360 | 1.50 | 14.0K | 445,990 | D | ↗ |
| 2025-12-18 | Caggiano Anthony | Officer | F-InKind | D | Common Stock | 20,280 | 1.50 | 30.4K | 507,993 | D | ↗ |
| 2025-09-19 | Fletcher Aaron G.L. | Director / 10% Owner | M-Exempt | A | Common Stock | 7,729 | 0.84 | 6.5K | 56,229 | D | ↗ |
| 2025-07-29 | Ricciardi Lisa | Director / Officer | A-Award | A | Common Stock | 75,000 | 0.00 | — | 962,066 | D | ↗ |
| 2025-07-29 | Doyle John Brendan | Officer | A-Award | A | Common Stock | 30,000 | 0.00 | — | 434,710 | D | ↗ |
| 2025-07-29 | Caggiano Anthony | Officer | A-Award | A | Common Stock | 65,000 | 0.00 | — | 483,554 | D | ↗ |
| 2025-06-18 | Wallace Peggy | Director | A-Award | A | Common Stock | 34,000 | 0.00 | — | 86,461 | D | ↗ |
| 2025-06-18 | RICHSTONE ELLEN B | Director | A-Award | A | Common Stock | 34,000 | 0.00 | — | 58,500 | D | ↗ |
| 2025-06-18 | Monia Brett P | Director | A-Award | A | Common Stock | 34,000 | 0.00 | — | 48,500 | D | ↗ |
| 2025-06-18 | Kreis Leslie W. | Director / 10% Owner | A-Award | A | Common Stock | 34,000 | 0.00 | — | 48,500 | I | ↗ |
| 2025-06-18 | Khattar Jack A. | Director | A-Award | A | Common Stock | 34,000 | 0.00 | — | 48,500 | D | ↗ |
| 2025-06-18 | Fletcher Aaron G.L. | Director / 10% Owner | A-Award | A | Common Stock | 34,000 | 0.00 | — | 48,500 | D | ↗ |
| 2025-05-01 | Doyle John Brendan | Officer | F-InKind | D | Common Stock | 9,692 | 0.45 | 4.3K | 404,710 | D | ↗ |
| 2025-02-15 | Ricciardi Lisa | Director / Officer | F-InKind | D | Common Stock | 6,619 | 0.59 | 3.9K | 887,066 | D | ↗ |
| 2025-02-15 | Doyle John Brendan | Officer | F-InKind | D | Common Stock | 1,723 | 0.59 | 1.0K | 414,402 | D | ↗ |
| 2025-02-15 | Caggiano Anthony | Officer | F-InKind | D | Common Stock | 5,296 | 0.59 | 3.1K | 418,554 | D | ↗ |
| 2025-02-04 | Ricciardi Lisa | Director / Officer | A-Award | A | Common Stock | 631,300 | 0.00 | — | 893,685 | D | ↗ |
| 2025-02-04 | Doyle John Brendan | Officer | A-Award | A | Common Stock | 295,000 | 0.00 | — | 416,125 | D | ↗ |
| 2025-02-04 | Caggiano Anthony | Officer | A-Award | A | Common Stock | 295,000 | 0.00 | — | 423,850 | D | ↗ |
| 2025-02-03 | Ricciardi Lisa | Director / Officer | F-InKind | D | Common Stock | 28,960 | 0.67 | 19.3K | 262,385 | D | ↗ |
| 2025-02-03 | Caggiano Anthony | Officer | F-InKind | D | Common Stock | 12,779 | 0.67 | 8.5K | 128,850 | D | ↗ |
| 2025-01-31 | Ricciardi Lisa | Director / Officer | P-Purchase | A | Common Stock | 38,851 | 0.77 | 30.0K | 38,851 | I | ↗ |
| 2024-06-07 | Wallace Peggy | Director | A-Award | A | Stock Option (right to buy) | 8,500 | 1.95 | 16.6K | 8,500 | — | ↗ |
| 2024-06-07 | RICHSTONE ELLEN B | Director | A-Award | A | Stock Option (right to buy) | 8,500 | 1.95 | 16.6K | 8,500 | — | ↗ |
| 2024-06-07 | Monia Brett P | Director | A-Award | A | Stock Option (right to buy) | 8,500 | 1.95 | 16.6K | 8,500 | — | ↗ |
| 2024-06-07 | Kreis Leslie W. | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 8,500 | 1.95 | 16.6K | 8,500 | — | ↗ |
| 2024-06-07 | Khattar Jack A. | Director | A-Award | A | Common Stock | 8,500 | 0.00 | — | 14,500 | — | ↗ |
| 2024-06-07 | Fletcher Aaron G.L. | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 8,500 | 1.95 | 16.6K | 8,500 | — | ↗ |
| 2024-05-01 | Doyle John Brendan | Officer | F-InKind | D | Common Stock | 8,699 | 1.95 | 17.0K | 121,125 | — | ↗ |
| 2024-03-14 | Ricciardi Lisa | Director / Officer | P-Purchase | A | Common Stock | 5,700 | 1.75 | 10.0K | 291,345 | — | ↗ |
| 2024-02-15 | Ricciardi Lisa | Director / Officer | A-Award | A | Common Stock | 75,000 | 0.00 | — | 285,645 | — | ↗ |
| 2024-02-15 | Doyle John Brendan | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 129,824 | — | ↗ |
| 2024-02-15 | Caggiano Anthony | Officer | A-Award | A | Common Stock | 60,000 | 0.00 | — | 141,629 | — | ↗ |
| 2024-02-03 | Ricciardi Lisa | Director / Officer | F-InKind | D | Common Stock | 27,828 | 2.29 | 63.7K | 210,645 | — | ↗ |
| 2024-02-03 | Caggiano Anthony | Officer | F-InKind | D | Common Stock | 12,777 | 2.29 | 29.3K | 81,629 | — | ↗ |
| 2023-11-08 | Kreis Leslie W. | Director / 10% Owner | A-Award | A | Common Stock | 500,095 | 1.05 | 525.1K | 500,095 | — | ↗ |
| 2023-11-08 | Fletcher Aaron G.L. | Director / 10% Owner | A-Award | A | Common Stock | 500,095 | 1.05 | 525.1K | 500,095 | — | ↗ |
| 2023-11-08 | Bios Clinical Opportunity Fund, LP | Director / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 500,095 | — | ↗ |
| 2023-06-09 | Wallace Peggy | Director | A-Award | A | Stock Option (right to buy) | 6,000 | 2.77 | 16.6K | 6,000 | — | ↗ |
| 2023-06-09 | RICHSTONE ELLEN B | Director | A-Award | A | Stock Option (right to Buy) | 6,000 | 2.77 | 16.6K | 6,000 | — | ↗ |
| 2023-06-09 | Monia Brett P | Director | A-Award | A | Common Stock | 6,000 | 0.00 | — | 6,000 | — | ↗ |
| 2023-06-09 | Kreis Leslie W. | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 6,000 | 2.77 | 16.6K | 6,000 | — | ↗ |
| 2023-06-09 | Khattar Jack A. | Director | A-Award | A | Stock Option (right to buy) | 6,000 | 2.77 | 16.6K | 6,000 | — | ↗ |
| 2023-06-09 | Fletcher Aaron G.L. | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 6,000 | 2.77 | 16.6K | 6,000 | — | ↗ |
| 2023-05-01 | Doyle John Brendan | Officer | A-Award | A | Stock Option (right to buy) | 109,824 | 1.65 | 181.2K | 109,824 | — | ↗ |
| 2023-02-03 | Ricciardi Lisa | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 213,973 | 2.12 | 453.6K | 213,973 | — | ↗ |
| 2023-02-03 | Caggiano Anthony | Officer | A-Award | A | Stock Option (Right to Buy) | 94,406 | 2.12 | 200.1K | 94,406 | — | ↗ |
| 2022-11-29 | RICHSTONE ELLEN B | Director | P-Purchase | A | Common Stock | 10,000 | 2.66 | 26.6K | 10,000 | — | ↗ |
| 2022-11-28 | Kreis Leslie W. | Director | P-Purchase | A | Common Stock | 12,220 | 2.65 | 32.4K | 2,021,906 | — | ↗ |
| 2022-11-28 | Fletcher Aaron G.L. | Director | P-Purchase | A | Common Stock | 12,220 | 2.65 | 32.4K | 2,021,906 | — | ↗ |
| 2022-11-16 | Kreis Leslie W. | Director | P-Purchase | A | Common Stock | 8,722 | 1.40 | 12.2K | 324,760 | — | ↗ |
| 2022-11-16 | Fletcher Aaron G.L. | Director | P-Purchase | A | Common Stock | 8,269 | 1.40 | 11.6K | 307,877 | — | ↗ |
| 2022-11-15 | Wallace Peggy | Director | P-Purchase | A | Common Stock | 12,500 | 1.20 | 15.0K | 37,961 | — | ↗ |
| 2022-11-15 | Ricciardi Lisa | Officer | P-Purchase | A | Common Stock | 12,000 | 1.30 | 15.6K | 24,500 | — | ↗ |
| 2022-11-15 | Kreis Leslie W. | Director | P-Purchase | A | Common Stock | 174,700 | 1.20 | 209.6K | 299,608 | — | ↗ |
| 2022-11-15 | Fletcher Aaron G.L. | Director | P-Purchase | A | Common Stock | 174,700 | 1.20 | 209.6K | 299,608 | — | ↗ |
| 2022-08-12 | Einhorn Andrew J. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-06-10 | Wallace Peggy | Director | A-Award | A | Stock Option (right to buy) | 8,335 | 0.00 | — | 8,335 | — | ↗ |
| 2022-06-10 | Ricciardi Lisa | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 0.00 | — | 150,000 | — | ↗ |
| 2022-06-10 | RICHSTONE ELLEN B | Director | A-Award | A | Stock Option (right to buy) | 8,335 | 0.00 | — | 8,335 | — | ↗ |
| 2022-06-10 | Monia Brett P | Director | A-Award | A | Stock Option (right to buy) | 8,335 | 0.00 | — | 8,335 | — | ↗ |
| 2022-06-10 | Khattar Jack A. | Director | A-Award | A | Stock Option (right to buy) | 8,335 | 0.00 | — | 8,335 | — | ↗ |
| 2022-06-10 | Fletcher Aaron G.L. | Director / 10% Owner | J-Other | A | Stock Option (right to buy) | 2,469 | 1.98 | 4.9K | 3,614 | — | ↗ |
| 2022-06-10 | Cavu Advisors, LLC | Director | J-Other | D | Stock Option (right to buy) | 2,469 | 0.00 | — | 8,585 | — | ↗ |
| 2022-03-23 | O'Brien James Michael | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-03-23 | Caggiano Anthony | Officer | A-Award | A | Stock Option (right to buy) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-01-31 | Fletcher Aaron G.L. | Director / 10% Owner | J-Other | A | Stock Option (right to buy) | 1,145 | 1.75 | 2.0K | 1,145 | — | ↗ |
| 2022-01-31 | BP Directors, LP | — | — | I | Stock Option (right to buy) | 1,145 | 1.75 | 2.0K | 0 | — | ↗ |
| 2021-11-01 | RICHSTONE ELLEN B | Director | A-Award | A | Stock Option (right to buy) | 16,670 | 12.10 | 201.7K | 16,670 | — | ↗ |
| 2021-11-01 | Caggiano Anthony | Officer | A-Award | A | Stock Option (right to buy) | 161,676 | 12.10 | 1.96M | 161,676 | — | ↗ |
| 2021-10-13 | Wallace Peggy | Director | P-Purchase | A | Common Stock | 3,000 | 12.00 | 36.0K | 3,000 | — | ↗ |
| 2021-10-13 | Ricciardi Lisa | Director / Officer | P-Purchase | A | Common Stock | 12,500 | 12.00 | 150.0K | 12,500 | — | ↗ |
| 2021-10-13 | Ogden CAP Associates, LLC | 10% Owner | S-Sale | D | Common Stock | 74 | 12.00 | 888.60 | 2,210,377 | — | ↗ |
| 2021-10-13 | O'Brien James Michael | Officer | P-Purchase | A | Common Stock | 5,000 | 12.00 | 60.0K | 5,000 | — | ↗ |
| 2021-10-13 | Golden Seeds Cognition Therapeutics LLC | 10% Owner | C-Conversion | D | Series A-2 Convertible Preferred Stock | 542,496 | 0.00 | — | 0 | — | ↗ |
| 2021-10-13 | Fletcher Aaron G.L. | Director / 10% Owner | C-Conversion | A | Common Stock | 1,424,014 | 0.00 | — | 1,424,014 | — | ↗ |
| 2021-10-13 | Breedlove Mark H. | Director | C-Conversion | A | Common Stock | 36,714 | 0.00 | — | 81,520 | — | ↗ |
| 2021-10-13 | BIOS Memory SPV I, LP | 10% Owner | C-Conversion | A | Common Stock | 34,238 | 0.00 | — | 34,238 | — | ↗ |
| 2021-10-07 | Wallace Peggy | Director | — | D | Stock Option (right to buy) | 7,729 | 0.87 | 6.7K | 0 | — | ↗ |
| 2021-10-07 | Ricciardi Lisa | Director / Officer | — | D | Stock Option (right to buy) | 7,729 | 1.07 | 8.3K | 0 | — | ↗ |
| 2021-10-07 | Ogden CAP Associates, LLC | 10% Owner | — | D | Series B Convertible Preferred Stock | 1,263,575 | 0.00 | — | 0 | — | ↗ |
| 2021-10-07 | O'Brien James Michael | Officer | — | D | Stock Option (right to buy) | 130,931 | 1.07 | 140.1K | 0 | — | ↗ |
| 2021-10-07 | Monia Brett P | Director | — | D | Stock Option (right to buy) | 41,737 | 1.20 | 50.1K | 0 | — | ↗ |
| 2021-10-07 | Khattar Jack A. | Director | — | D | Stock Option (right to buy) | 41,737 | 1.20 | 50.1K | 0 | — | ↗ |
| 2021-10-07 | Golden Seeds Cognition Therapeutics LLC | 10% Owner | — | D | Series A-2 Convertible Preferred Stock | 167,720 | 0.00 | — | 0 | — | ↗ |
| 2021-10-07 | Fletcher Aaron G.L. | Director | — | I | Simple Agreement for Future Equity | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-07 | Breedlove Mark H. | Director | — | I | Series A-1 Convertible Preferred Stock | 44,806 | 0.00 | — | 0 | — | ↗ |
| 2021-10-07 | BIOS Memory SPV I, LP | 10% Owner | — | I | Series B Convertible Preferred Stock | 245,029 | 0.00 | — | 0 | — | ↗ |
| 2016-03-15 | Ogden CAP Associates, LLC | 10% Owner | — | D | Warrant (Right to Buy) | 27,471 | 0.03 | 824.13 | 0 | — | ↗ |
| 2016-03-15 | Golden Seeds Cognition Therapeutics LLC | 10% Owner | — | D | Warrant (Right to Buy) | 12,276 | 0.03 | 368.28 | 0 | — | ↗ |
| 2016-03-15 | Fletcher Aaron G.L. | Director | — | I | Warrant (Right to Buy) | 33,495 | 0.03 | 1.0K | 0 | — | ↗ |
| 2016-03-15 | Breedlove Mark H. | Director | — | I | Warrant (Right to Buy) | 4,354 | 0.03 | 130.62 | 0 | — | ↗ |
| 2016-03-15 | BIOS Memory SPV I, LP | 10% Owner | — | I | Warrant (Right to Buy) | 33,495 | 0.03 | 1.0K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
73.58M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Lisa Ricciardi President and Chief Executive Officer | 651.0K | — | 396.5K | — | 393.9K | 18.3K | 1.46M | 27.16% | ↗ |
| 2 | 2025 | Anthony Caggiano, M.D., Ph.D. Chief Medical Officer | 503.0K | — | 185.3K | — | 221.3K | 18.3K | 927.9K | 19.97% | ↗ |
| 3 | 2025 | John Doyle Chief Financial Officer | 460.6K | — | 185.3K | — | 202.7K | 18.3K | 866.8K | 21.37% | ↗ |
| 4 | 2024 | Lisa Ricciardi President and Chief Executive Officer | 629.0K | — | 445.5K | 117.1K | 304.4K | 18.3K | 1.51M | 37.15% | ↗ |
| 5 | 2024 | Anthony Caggiano, M.D., Ph.D. Chief Medical Officer | 486.0K | — | 376.2K | 93.7K | 172.1K | 18.3K | 1.15M | 40.99% | ↗ |
| 6 | 2024 | John Doyle Chief Financial Officer | 445.0K | — | 158.4K | 31.2K | 156.6K | 18.3K | 809.6K | 23.42% | ↗ |
| 7 | 2023 | Lisa Ricciardi President and Chief Executive Officer | 586.6K | — | 453.6K | 352.9K | 249.3K | 18.3K | 1.66M | 48.57% | ↗ |
| 8 | 2023 | Anthony Caggiano, M.D., Ph.D. Chief Medical Officer | 446.3K | — | 200.1K | 155.7K | 151.7K | 18.3K | 972.1K | 36.61% | ↗ |
| 9 | 2023 | John Doyle Chief Financial Officer | 276.7K | 40.0K | 181.2K | 141.2K | 94.1K | 4.2K | 737.3K | 43.73% | ↗ |
| 10 | 2022 | Lisa Ricciardi President and Chief Executive Officer | 550.1K | — | — | 220.5K | 225.6K | 18.3K | 1.01M | 21.73% | ↗ |
| 11 | 2022 | James O’Brien Former Chief Financial Officer | 253.4K | — | — | 115.6K | — | 327.3K | 696.2K | 16.60% | ↗ |
| 12 | 2022 | Anthony Caggiano, M.D., Ph.D. Chief Medical Officer | 424.2K | — | — | 57.8K | 136.0K | 18.3K | 636.3K | 9.08% | ↗ |
| 13 | 2022 | Andrew Einhorn Interim Chief Financial Officer | 319.5K | — | — | — | — | — | 319.5K | 0.00% | ↗ |
| 14 | 2021 | Lisa Ricciardi President and Chief Executive Officer | 409.4K | — | — | 10.66M | 256.3K | 11.6K | 11.34M | 94.03% | ↗ |
| 15 | 2021 | Anthony Caggiano, M.D., Ph.D. Chief Medical Officer | 92.8K | — | — | 1.59M | — | 1.3K | 1.68M | 94.41% | ↗ |
| 16 | 2021 | James O’Brien Chief Financial Officer | 348.8K | — | — | 522.8K | 155.0K | 11.6K | 1.04M | 50.36% | ↗ |
| 17 | 2021 | James O’Brien Former Chief Financial Officer | 348.8K | — | — | 522.8K | 155.0K | 11.6K | 1.04M | 50.36% | ↗ |
| 18 | 2020 | Lisa Ricciardi President and Chief Executive Officer | 287.4K | — | — | 901.9K | 79.9K | 3.4K | 1.27M | 70.87% | ↗ |
| 19 | 2020 | James O’Brien Chief Financial Officer | 340.0K | — | — | — | 70.9K | 7.3K | 418.2K | 0.00% | ↗ |
| 20 | 2020 | Anthony Caggiano, M.D., Ph.D. Chief Medical Officer | 370.0K | — | — | — | — | 11.4K | 381.4K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Lisa Ricciardi | Chief Executive Officer, President & Director | 1M | female |
| Anthony O. Caggiano | Chief Medical Officer | 742.6K | — |
| John Brendan Doyle | Chief Financial Officer | 681.5K | male |
| Anita Cornet | Head of Quality | — | female |
| Bobby Horn | Corporate Controller | — | male |
| Steven A. Weissman | Vice President & Head of CMC | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CGTX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
